{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:52:10Z","timestamp":1791301930780,"version":"4.1.0"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Neurosci."],"abstract":"<jats:p>\n                    Spinal muscular atrophy (SMA) has become a paradigm for precision medicine following the development of transformative therapies targeting the disease-causing deficiency of survival motor neuron (SMN) protein. As more than 98% of SMA cases arise from mutations in the\n                    <jats:italic>SMN1<\/jats:italic>\n                    gene, restoration of SMN expression through nusinersen (Spinraza; Biogen, Cambridge, MA), risdiplam (Evrysdi; Roche, Basel, Switzerland) and onasemnogene abeparvovec (Zolgensma and Itvisma; AveXis, Novartis, Chicago, IL) has produced unprecedented clinical benefits and established SMA as the first treatable motor neuron disease. To date, therapeutic success has focused on rescuing motor neurons, the principal site of clinical pathology. However, growing evidence indicates that SMA is a multisystem disorder in which pathological changes extend beyond the motor unit. In particular, vascular pathology has emerged as a recurring feature across numerous affected tissues. Vascular abnormalities have been identified throughout the neuromuscular system, including the spinal cord and skeletal muscle, as well as in systemic organs such as the heart, kidney, gastrointestinal tract and spleen. Experimental studies suggest that endothelial dysfunction is a direct consequence of SMN deficiency, impairing angiogenesis, vascular maturation and vessel stability, while patient-derived biomarkers, including retinal vascular imaging and elevated circulating endothelial cells (CEC), provide evidence of ongoing endothelial dysfunction in patients. These vascular abnormalities have the potential to compromise tissue perfusion, promote local hypoxia, disrupt barrier integrity and enhance inflammatory signaling, thereby exacerbating disease progression. Collectively, the evidence suggests that SMN-dependent vascular pathology may represent an under-recognized feature of SMA pathogenesis and a potential therapeutic target. Here, we review the current evidence for vascular pathology in SMA, discuss its implications for disease progression, long-term patient outcomes and therapeutic response, and consider whether vascular abnormalities are adequately addressed by existing SMN-restorative therapies.\n                  <\/jats:p>","DOI":"10.3389\/fncel.2026.1933459","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:54:35Z","timestamp":1791298475000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of vascular pathology in SMA: implications for pathogenesis and treatment"],"prefix":"10.3389","volume":"20","author":[{"given":"Simon H.","family":"Parson","sequence":"first","affiliation":[{"name":"Institute of Education in Healthcare and Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen","place":["Aberdeen, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazel","family":"Allardyce","sequence":"additional","affiliation":[{"name":"School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow","place":["Glasgow, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"20232031","DOI":"10.1038\/s41401-024-01295-8","article-title":"Endothelial dysfunction: mechanisms and contribution to diseases","volume":"45","author":"Ajoolabady","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"B2","unstructured":"Alberts\n              B.\n            \n            \n              Johnson\n              A.\n            \n            \n              Lewis\n              J.\n            \n            \n              Raff\n              M.\n            \n            \n              Roberts\n              K.\n            \n            \n              Walter\n              P.\n            \n          \n          Blood vessels and endothelial cells\n          \n          2002"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1093\/hmg\/ddaa126","article-title":"Renal pathology in a mouse model of severe spinal muscular atrophy is associated with downregulation of glial cell-line derived neurotrophic factor (GDNF)","volume":"29","author":"Allardyce","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40478-026-02232-y","article-title":"Microvascular pathology in the spinal cord of severe spinal muscular atrophy patients","volume":"14","author":"Allardyce","year":"2026","journal-title":"Acta Neuropathol. Commun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e13013","DOI":"10.1111\/nan.13013","article-title":"A reassessment of spinal cord pathology in severe infantile spinal muscular atrophy","volume":"50","author":"Allardyce","year":"2024","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jpeds.2009.01.071","article-title":"Vascular perfusion abnormalities in infants with spinal muscular atrophy","volume":"155","author":"Araujo","year":"2009","journal-title":"J. Pediatr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1001\/jamapediatrics.2024.1911","article-title":"Newborn screening and birth prevalence for spinal muscular atrophy in the US","volume":"178","author":"Belter","year":"2024","journal-title":"JAMA Pediatr."},{"key":"B8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41434-022-00341-6","article-title":"Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study","volume":"30","author":"Bitetti","year":"2022","journal-title":"Gene Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"E5863","DOI":"10.1073\/pnas.1509758112","article-title":"Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II\/III spinal muscular atrophy","volume":"112","author":"Bogdanik","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"B10","doi-asserted-by":"publisher","first-page":"181888","DOI":"10.3389\/fmolb.2016.00007","article-title":"Copy number variations in the survival motor neuron genes: implications for spinal muscular atrophy and other neurodegenerative diseases","volume":"3","author":"Butchbach","year":"2016","journal-title":"Front. Mol. Biosci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1212\/NXG.0000000000000361","article-title":"Digital necrosis in an infant with severe spinal muscular atrophy","volume":"5","author":"Carrasco","year":"2019","journal-title":"Neurol. Genet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1007\/s00018-018-2849-1","article-title":"The role of survival motor neuron protein (SMN) in protein homeostasis","volume":"75","author":"Chaytow","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN Rx) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/neurosci3010001","article-title":"Blood-spinal cord barrier: its role in spinal disorders and emerging therapeutic strategies","volume":"3","author":"Chopra","year":"2021","journal-title":"NeuroSci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/hmg\/6.8.1205","article-title":"The survival motor neuron protein in spinal muscular atrophy","volume":"6","author":"Coovert","year":"1997","journal-title":"Hum. Mol. Genet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.3390\/nu13072400","article-title":"Nutritional, gastrointestinal and endo-metabolic challenges in the management of children with spinal muscular atrophy type 1","volume":"13","author":"Corsello","year":"2021","journal-title":"Nutrients"},{"key":"B17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1006\/nbdi.1996.0010","article-title":"\u201cThe neurobiology of childhood spinal muscular atrophy,\u201d","author":"Crawford","year":"1996","journal-title":"Neurobiology of Disease, Vol. 3, No. 2"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1161\/CIRCULATIONAHA.106.652859","article-title":"Endothelial function and dysfunction: testing and clinical relevance","volume":"115","author":"Deanfield","year":"2007","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3233\/JND-200493","article-title":"Blood flow to the spleen is altered in a mouse model of spinal muscular atrophy","volume":"7","author":"Deguise","year":"2020","journal-title":"J. Neuromuscl. Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1056\/NEJMra0910283","article-title":"Hypoxia and inflammation","volume":"364","author":"Eltzschig","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cca.2006.05.016","article-title":"Circulating endothelial cells: a novel marker of endothelial damage","volume":"373","author":"Erdbruegger","year":"2006","journal-title":"Clin. Chim. Acta"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms24032909","article-title":"Endothelial dysfunction in neurodegenerative diseases","volume":"24","author":"Fang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1124\/dmd.121.000563","article-title":"\u201cAddressing today's absorption, distribution, metabolism, and excretion (ADME) challenges in the translation of in vitro ADME characteristics to humans: a case study of the SMN2 mRNA splicing modifier risdiplam,\u201d","author":"Fowler","year":"2022","journal-title":"Drug Metabolism and Disposition, Vol. 50, No. 1"},{"key":"B25","doi-asserted-by":"publisher","first-page":"46829","DOI":"10.31083\/RCM46829","article-title":"Coronary microvascular dysfunction in cardiomyopathies: insights on clinical and prognostic roles","volume":"27","author":"Giacobbe","year":"2026","journal-title":"Rev. Cardiovasc. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/j.2040-4603.2015.tb00651.x","article-title":"The gastrointestinal circulation: physiology and pathophysiology","volume":"5","author":"Granger","year":"2015","journal-title":"Compr. Physiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1093\/hmg\/ddy195","article-title":"Temporal and tissue-specific variability of SMN protein levels in mouse models of spinal muscular atrophy","volume":"27","author":"Groen","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.molmed.2012.11.002","article-title":"Spinal muscular atrophy: going beyond the motor neuron","volume":"19","author":"Hamilton","year":"2013","journal-title":"Trends Mol. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S0387-7604(02)00103-1","article-title":"Oxidative stress and disturbed glutamate transport in spinal muscular atrophy","volume":"24","author":"Hayashi","year":"2002","journal-title":"Brain Dev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e17514","DOI":"10.1371\/journal.pone.0017514","article-title":"Scaling of brain metabolism with a fixed energy budget per neuron: implications for neuronal activity, plasticity and evolution","volume":"6","author":"Herculano-Houzel","year":"2011","journal-title":"PLoS ONE"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/acn3.51134","article-title":"Widespread tissue hypoxia dysregulates cell and metabolic pathways in SMA","volume":"7","author":"Hernandez-Gerez","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/71709","article-title":"A mouse model for spinal muscular atrophy","volume":"24","author":"Hsieh-Li","year":"2000","journal-title":"Nat. Genet."},{"key":"B33","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1101\/gad.256644.114","article-title":"Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic mouse models","volume":"29","author":"Hua","year":"2015","journal-title":"Genes Dev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model","volume":"478","author":"Hua","year":"2011","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","first-page":"304","DOI":"10.18632\/aging.100292","article-title":"Regulation of life span by mitochondrial respiration: the HIF-1 and ROS connection","volume":"3","author":"Hwang","year":"2011","journal-title":"Aging"},{"key":"B37","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/gt.2017.46","article-title":"Developmental regulation of SMN expression: pathophysiological implications and perspectives for therapy development in spinal muscular atrophy","volume":"24","author":"Jablonka","year":"2017","journal-title":"Gene Therapy"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1089\/neu.2020.7413","article-title":"Blood-spinal cord barrier in spinal cord injury: a review","volume":"38","author":"Jin","year":"2021","journal-title":"J. Neurotrauma"},{"key":"B39","doi-asserted-by":"publisher","first-page":"100938","DOI":"10.1016\/j.preteyeres.2020.100938","article-title":"Past, present and future role of retinal imaging in neurodegenerative disease","volume":"83","author":"Kashani","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"E379","DOI":"10.1152\/ajpendo.00443.2015","article-title":"Muscle microvasculature's structural and functional specializations facilitate muscle metabolism","volume":"310","author":"Kusters","year":"2015","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"B41","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1161\/01.RES.0000259593.07661.1e","article-title":"Endothelial cell migration during angiogenesis","volume":"100","author":"Lamalice","year":"2007","journal-title":"Circ. Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"eaau6085","DOI":"10.1126\/sciimmunol.aau6085","article-title":"Structure and function of the immune system in the spleen","volume":"4","author":"Lewis","year":"2019","journal-title":"Sci. Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e0213680","DOI":"10.1371\/journal.pone.0213680","article-title":"Systemic nature of spinal muscular atrophy revealed by studying insurance claims","volume":"14","author":"Lipnick","year":"2019","journal-title":"PLoS ONE"},{"key":"B44","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ana.25596","article-title":"Global central nervous system atrophy in spinal muscular atrophy type 0","volume":"86","author":"Maeda","year":"2019","journal-title":"Ann. Neurol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/eye.1990.33","article-title":"The fractal properties of retinal vessels: embryological and clinical implications","volume":"4","author":"Mainster","year":"1990","journal-title":"Eye"},{"key":"B46","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/0883073820928784","article-title":"Clinical course in a patient with spinal muscular atrophy type 0 treated with nusinersen and onasemnogene abeparvovec","volume":"35","author":"Matesanz","year":"2020","journal-title":"J. Child Neurol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/joa.12793","article-title":"Developmental and degenerative cardiac defects in the Taiwanese mouse model of severe spinal muscular atrophy","volume":"232","author":"Maxwell","year":"2018","journal-title":"J. Anat."},{"key":"B48","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/jnc.13861","article-title":"Trafficking of adeno-associated virus vectors across a model of the blood\u2013brain barrier; a comparative study of transcytosis and transduction using primary human brain endothelial cells","volume":"140","author":"Merkel","year":"2017","journal-title":"J. Neurochem."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm9072222","article-title":"New treatments in spinal muscular atrophy: positive results and new challenges","volume":"9","author":"Messina","year":"2020","journal-title":"J. Clin. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1399-0004.1990.tb03553.x","article-title":"Spinal muscular atrophy type I combined with atrial septal defect in three sibs","volume":"38","author":"M\u00f8ller","year":"1990","journal-title":"Clin. Genet."},{"key":"B51","doi-asserted-by":"publisher","first-page":"9107","DOI":"10.3390\/ijms25169107","article-title":"Fenestrated endothelial cells across organs: insights into kidney function and disease","volume":"25","author":"Mou","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e1462","DOI":"10.1002\/wsbm.1462","article-title":"Skeletal muscle: a review of molecular structure and function, in health and disease","volume":"12","author":"Mukund","year":"2019","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/brainsci11030296","article-title":"Cerebrospinal fluid parameters in antisense oligonucleotide-treated adult 5q-spinal muscular atrophy patients","volume":"11","author":"M\u00fcschen","year":"2021","journal-title":"Brain Sci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/hmg\/ddaf006","article-title":"Alterations in cardiac function correlate with a disruption in fatty acid metabolism in a mouse model of SMA","volume":"34","author":"Nair","year":"2025","journal-title":"Hum. Mol. Genet."},{"key":"B55","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/ana.21449","article-title":"Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition","volume":"64","author":"Narver","year":"2008","journal-title":"Ann. Neurol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"194","DOI":"10.5863\/1551-6776-24.3.194","article-title":"Nusinersen: a novel antisense oligonucleotide for the treatment of spinal muscular atrophy","volume":"24","author":"Neil","year":"2019","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/NXG.0000000000000353","article-title":"Impaired kidney structure and function in spinal muscular atrophy","volume":"5","author":"Nery","year":"2019","journal-title":"Neurol. Genet."},{"key":"B58","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.1093\/nar\/gkad259","article-title":"Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy","volume":"51","author":"Ottesen","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"72r","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"729","DOI":"10.2147\/VHRM.S519426","article-title":"Vascular endothelium in health and disease: structure, function, assessment and role in metabolic disorders","volume":"21","author":"Pluta","year":"2025","journal-title":"Vasc. Health Risk Manag."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/prp2.447","article-title":"Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs","volume":"6","author":"Poirier","year":"2018","journal-title":"Pharmacol. Res. Perspect."},{"key":"B62","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1172\/JCI124120","article-title":"Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment","volume":"129","author":"Ramos","year":"2019","journal-title":"J. Clin. Invest."},{"key":"B63","doi-asserted-by":"publisher","first-page":"100084","DOI":"10.1016\/j.hsr.2023.100084","article-title":"Endothelial dysfunction and its relation in different disorders: recent update","volume":"7","author":"Ray","year":"2023","journal-title":"Health Sci. Rev."},{"key":"B64","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41434-022-00338-1","article-title":"Central and peripheral delivered AAV9-SMN are both efficient but target different pathomechanisms in a mouse model of spinal muscular atrophy","volume":"29","author":"Reilly","year":"2022","journal-title":"Gene Ther."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/hmg\/ddq023","article-title":"SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy","volume":"19","author":"Riessland","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"B66","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/jmg.2008.057950","article-title":"Congenital heart disease is a feature of severe infantile spinal muscular atrophy","volume":"45","author":"Rudnik-Sch\u00f6neborn","year":"2008","journal-title":"J. Med. Genet."},{"key":"B67","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/mus.21654","article-title":"Digital necroses and vascular thrombosis in severe spinal muscular atrophy","volume":"42","author":"Rudnik-Sch\u00f6neborn","year":"2010","journal-title":"Muscle Nerve"},{"key":"B68","doi-asserted-by":"publisher","first-page":"E42","DOI":"10.1002\/mus.26457","article-title":"Resolution of skin necrosis after nusinersen treatment in an infant with spinal muscular atrophy","volume":"59","author":"Salmin","year":"2019","journal-title":"Muscle Nerve"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.yjmcc.2012.01.005","article-title":"Partial restoration of cardio-vascular defects in a rescued severe model of spinal muscular atrophy","volume":"52","author":"Shababi","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/joa.12083","article-title":"Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?","volume":"224","author":"Shababi","year":"2014","journal-title":"J. Anat."},{"key":"B71","doi-asserted-by":"publisher","first-page":"101379","DOI":"10.1016\/j.omtm.2024.101379","article-title":"Patient-specific responses to SMN2 splice-modifying treatments in spinal muscular atrophy fibroblasts","volume":"32","author":"Signoria","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B72","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/978-1-4615-4863-8_2","article-title":"Oxygen and ion concentrations in normoxic and hypoxic brain cells","volume":"454","author":"Silver","year":"1998","journal-title":"Adv. Exp. Med. Biol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2633105520973985","article-title":"The first orally deliverable small molecule for the treatment of spinal muscular atrophy","volume":"15","author":"Singh","year":"2020","journal-title":"Neurosci. Insights"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0155032","article-title":"Histopathological defects in intestine in severe spinal muscular atrophy mice are improved by systemic antisense oligonucleotide treatment","volume":"11","author":"Sintusek","year":"2016","journal-title":"PLoS ONE"},{"key":"B75","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/ana.24549","article-title":"Vascular defects and spinal cord hypoxia in spinal muscular atrophy","volume":"79","author":"Somers","year":"2016","journal-title":"Ann. Neurol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.nmd.2011.10.021","article-title":"Density, calibre and ramification of muscle capillaries are altered in a mouse model of severe spinal muscular atrophy","volume":"22","author":"Somers","year":"2012","journal-title":"Neuromuscul. Disord."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1167\/iovs.10-5176","article-title":"The mouse retina as an angiogenesis model","volume":"51","author":"Stahl","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B78","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/joa.12546","article-title":"Survival of motor neurone protein is required for normal postnatal development of the spleen","volume":"230","author":"Thomson","year":"2017","journal-title":"J. Anat."},{"key":"B79","doi-asserted-by":"publisher","first-page":"35r","DOI":"10.1126\/scitranslmed.3000830","article-title":"Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy","volume":"2","author":"Valori","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"268","DOI":"10.20517\/jtgg.2025.56","article-title":"SMN2 as a therapeutic target in spinal muscular atrophy: advances in gene expression modulation","volume":"9","author":"Virata","year":"2025","journal-title":"J. Transl. Genet. Genom."},{"key":"B81","doi-asserted-by":"publisher","first-page":"e651","DOI":"10.1002\/mco2.651","article-title":"Endothelial dysfunction: molecular mechanisms and clinical implications","volume":"5","author":"Wang","year":"2024","journal-title":"Med. Comm."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e0128007","DOI":"10.1371\/journal.pone.0128007","article-title":"Abbreviated exposure to hypoxia is sufficient to induce CNS dysmyelination, modulate spinal motor neuron composition, and impair motor development in neonatal mice","volume":"10","author":"Watzlawik","year":"2015","journal-title":"PLoS ONE"},{"key":"B83","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/pde.14538","article-title":"Skin necrosis in spinal muscular atrophy: case report and review of the literature","volume":"38","author":"Weissman","year":"2021","journal-title":"Pediatr. Dermatol."},{"key":"B84","first-page":"67","article-title":"Cardiac pathology in spinal muscular atrophy: a systematic review","volume-title":"Orphanet Journal of Rare Diseases","author":"Wijngaarde","year":"2017"},{"key":"B85","first-page":"1398","article-title":"Central nervous system pericytes in health and disease","volume-title":"Nature Neuroscience","author":"Winkler","year":"2011"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3389\/fneur.2019.01179","article-title":"Routine cerebrospinal fluid (CSF) parameters in patients with spinal muscular atrophy (SMA) treated with nusinersen","volume":"10","author":"Wurster","year":"2019","journal-title":"Front. Neurol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.pediatrneurol.2020.01.003","article-title":"Overturning the paradigm of spinal muscular atrophy as just a motor neuron disease","volume":"109","author":"Yeo","year":"2020","journal-title":"Pediatr. Neurol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/ana.25930","article-title":"Yeo and Darras: extraneuronal phenotypes of spinal muscular atrophy","volume":"89","author":"Yeo","year":"2021","journal-title":"Ann. Neurol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11940-026-00863-z","article-title":"Spinal muscular atrophy: advances in diagnosis, treatment, and emerging therapies","volume":"28","author":"Yu","year":"2026","journal-title":"Curr. Treat. Options Neurol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"e0298609","DOI":"10.1371\/journal.pone.0298609","article-title":"Exploration of adverse events associated with risdiplam use: retrospective cases from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database","volume":"19","author":"Yu","year":"2024","journal-title":"PLoS ONE"},{"key":"B91","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.3390\/medicina59122114","article-title":"Optical coherence tomography (OCT): a brief look at the uses and technological evolution of ophthalmology","volume":"59","author":"Zeppieri","year":"2023","journal-title":"Medicina"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1475884","DOI":"10.3389\/fphar.2024.1475884","article-title":"Comprehensive analysis of adverse events associated with onasemnogene abeparvovec (Zolgensma) in spinal muscular atrophy patients: insights from FAERS database","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1152318","DOI":"10.3389\/fped.2023.1152318","article-title":"Adverse events in the treatment of spinal muscular atrophy in children and adolescents with nusinersen: a systematic review and meta-analysis","volume":"11","author":"Zhong","year":"2023","journal-title":"Front. Pediatr."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI153430","article-title":"Microvasculopathy in SMA is driven by a reversible autonomous endothelial cell defect","volume":"132","author":"Zhou","year":"2022","journal-title":"J. Clin. Invest."},{"key":"B95","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1089\/hum.2012.211","article-title":"A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice","volume":"24","author":"Zhou","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"B96","doi-asserted-by":"publisher","first-page":"6265","DOI":"10.1093\/hmg\/ddv329","article-title":"Repeated low doses of morpholino antisense oligomer: an intermediate mouse model of spinal muscular atrophy to explore the window of therapeutic response","volume":"24","author":"Zhou","year":"","journal-title":"Hum. Mol. Genet."},{"key":"B97","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.1016\/j.nmd.2015.06.038","article-title":"Microvascular abnormality in spinal muscular atrophy and its response to antisense oligonucleotide therapy","volume":"25","author":"Zhou","year":"","journal-title":"Neuromuscul. Disord."}],"container-title":["Frontiers in Cellular Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fncel.2026.1933459\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:54:37Z","timestamp":1791298477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fncel.2026.1933459\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":97,"alternative-id":["10.3389\/fncel.2026.1933459"],"URL":"https:\/\/doi.org\/10.3389\/fncel.2026.1933459","relation":{},"ISSN":["1662-5102"],"issn-type":[{"value":"1662-5102","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"article-number":"1933459"}}